Damora Therapeutics (DMRA) Research & Development (2019 - 2026)

Damora Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $23.8 million for Q1 2026.

• Quarterly Research & Development rose 3406.93% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.0 million (up 983.37% YoY) and the FY2025 annual result came in at $26.9 million, up 320.08% from the prior year.
• Research & Development was $23.8 million for Q1 2026 at Damora Therapeutics, up from $23.3 million in the prior quarter.
• Across five years, Research & Development topped out at $23.8 million in Q1 2026 and bottomed at $678000.0 in Q1 2025.
• A 5-year average of $7.6 million and a median of $2.8 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development slumped 77.33% — and 2026, when it surged 3406.93%.
• Damora Therapeutics' Research & Development stood at $10.8 million in 2022, then plunged by 74.3% to $2.8 million in 2023, then plunged by 63.58% to $1.0 million in 2024, then jumped by 2213.29% to $23.3 million in 2025, then grew by 1.97% to $23.8 million in 2026.
• Business Quant data shows DMRA's Research & Development at $23.8 million in Q1 2026, $23.3 million in Q4 2025, and $1.4 million in Q3 2025.